[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053281":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":38,"responsibleParty":56,"collaborators":25,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":25,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":25,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":25,"overallStatus":78,"whyStopped":25,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Chengdu Suncadia Medicine Co., Ltd.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"single ascending dose (SAD) cohorts","EXPERIMENTAL","Subjects will be assigned to one of 5-6 planned dose cohorts and receive single dose of HRS-8797 or placebo",[13,14],"Drug: HRS-8797","Drug: Placebo",{"label":16,"type":10,"description":17,"interventionNames":18},"multiple ascending dose (MAD) cohorts","Subjects will be assigned to one of 3 planned dose cohorts and receive multiple doses of HRS-8797 or placebo",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","HRS-8797","Specified dose on specified days",[16,9],null,{"type":21,"name":27,"description":23,"armGroupLabels":28,"otherNames":25},"Placebo",[16,9],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Beibei Xu","CONTACT","+86 0518-82342973","beibei.xu.bx53@hengrui.com",{"name":36,"role":32,"phone":33,"phoneExt":25,"email":37},"Hongda Lin","hongda.lin@hengrui.com",[39],{"facility":40,"status":25,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"The First Hospital of Jilin University","Changchun","Jilin","130000","China","CN",{"type":47,"coordinates":48},"Point",[49,50],125.32278,43.88,{"lat":50,"lon":49},[53],{"name":54,"role":55,"phone":25,"phoneExt":25,"email":25},"Xiaojiao Li","PRINCIPAL_INVESTIGATOR",{"type":57,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100053281","phase-1-a-clinical-study-of-hrs-8797-in-healthy-participants-100053281",false,"NCT07698756","A Clinical Study of HRS-8797 in Healthy Participants","A Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect Following Single and Multiple Oral Doses of HRS-8797 Tablets in Healthy Subjects","Inclusion Criteria:\n\n1. Healthy men and women aged 18 to 55 years old at informed consent signing\n2. Male body weight ≥50 kg , female ≥45 kg; BMI 18 to 28 kg\u002Fm² at screening and baseline\n3. Have no clinically significant abnormalities at screening and baseline\n4. Fertile females and males with fertile female partners: effective contraception consent, and sustained until 4 weeks after the last dose (abstinence or highly effective contraception); no sperm\u002Fegg donation\n\nExclusion Criteria:\n\n1. A history or current severe diseases of multiple systems, or other diseases interfering with trial results.\n2. Severe infection, trauma, major surgery within 3 months before screening; planned surgery during the trial.\n3. Blood donation\u002Fsevere blood loss (≥400 mL) within 3 months, blood transfusion within 4 weeks before screening; planned blood donation during the trial.\n4. History of drug abuse\u002Fdependence; positive urine drug test at screening. Participation in other clinical trials within 3 months before screening or planned\n5. participation during the trial; within 5 half-lives of a prior drug (whichever is longer).\n6. Smoking history (≥5 cigarettes\u002Fday) within 4 weeks before screening; inability to abstain from tobacco during the trial;\n7. Positive for HBsAg, HIV antibody, Treponema pallidum antibody or HCV antibody at screening.\n8. Special dietary requirements and inability to comply with the unified diet.\n9. Difficulty in swallowing\u002Fvenous blood collection; intolerance to intensive blood sampling.\n10. Other circumstances deemed unsuitable for trial participation by Researcher.",true,"ALL","18 Years","55 Years",{"count":70,"type":71},74,"ESTIMATED","INTERVENTIONAL",[74],"PHASE1","The purpose of this phase I study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-8797 in healthy participants.",[77],"Atopic Dermatitis","NOT_YET_RECRUITING","2026-07-07",{"date":81,"type":82},"2026-07-13","ACTUAL",{"date":84,"type":71},"2026-07",{"date":86,"type":71},"2027-01",{"name":5,"class":6},1]